

Methylenetetrahydro folatereductase enzyme polymorphism associated with hyperhomocysteinemia in patients with stroke

Pramod Sudam Kamble^{1,*}, MP Bankar², DJ Trivedi³, Srirang Kulkarni⁴, Rakesh M⁵

¹Tutor, ^{3,4}Professor, SDM Institute of Medical sciences & Hospital, Dharwada, Karnataka, ⁵Associate Professor, SDM Institute of Medical sciences and Hospital, Dharwad, Karnataka, ²Professor, BJ Govt. Medical College, Pune, Maharashtra

***Corresponding Author:**

Email: pramod2011.1388@rediffmail.com

Abstract

Cerebrovascular stroke is complex heterogeneous multifactorial disorder associated with number of risk factors, including diabetes mellitus, hypertension, tobacco smoking or chewing; etc. MethylenetetrahydroFolate reductase (MTHFR) enzyme is one of the main regulatory enzymes required for the metabolism of homocysteine. An impaired function of this metabolic pathway leads to accumulation of homocysteine in blood. The elevation of plasma total homocysteine and deficiency of B-vitamins such as folic acid and vitamin B₁₂ factors associated with increased cardiovascular cerebrovascular and thromboembolic risk. A single nucleotide polymorphism of the MTHFR gene C677T causes reduction in enzyme activity. In the current study, we determined the prevalence of C677T mutation and correlated them to plasma total homocysteine, folic acid and vitamin B₁₂.

Total 50 cerebral stroke patients and 50 normal, healthy subjects acting as controls were taken for the study. The total homocysteine level in plasma was determined by high performance liquid chromatography (HPLC). Plasma level of folic acid and vitamin B₁₂ were estimated by competitive immunoassay using direct chemiluminescence technology. ARMS PCR was used to examine MTHFR C677T polymorphism.

Result shows concentration of significantly low plasma Folate levels, whereas vitamin B₁₂ does not show any significant difference in patients than controls. Total homocysteine concentrations in plasma were significantly higher in stroke as compared to controls. The variation in gene of MTHFR C677T and reduced level of B-vitamins have been related to hyperhomocysteinemia.

Keywords: Methylenetetrahydro Folate reductase, Hyperhomocysteinemia, Cerebral stroke, Folic acid, B₁₂ vitamin.

Introduction

Elevation of plasma total homocysteine concentration were recognised as major alterations in pathological vascular lesions and thromboembolic events develop in anteriorly located infarctions leads to arteriosclerosis and cerebrovascular stroke.¹ It is complex multifactorial disorder that causes clotting of blood and therefore rapid loss of brain functions, whose incidence increases by number of risk factors, including blood pressure, hypertension, tobacco smoking or chewing, diabetes mellitus etc.²

The Indian population has a higher than average incidence of cerebrovascular stroke events and evidence indicates that abnormalities of homocysteine metabolism may be a contributing factor.³

Over two decades, scientific study evident that homocysteine is an independent risk factor for vascular disorders like cardiovascular, cerebrovascular stroke, thromboembolism etc.^{4,5}

The enzyme methylenetetrahydro Folate reductase (MTHFR 1.1.1.171) is involved in homocysteine metabolism which catalyzes the reduction of 5, 10-methylenetetra hydro Folate to 5-methyltetrahydro Folate and acts as a carbon donor, 5-methyltetrahydro Folate, is predominant form of Folate in circulation, and act as methyl donor for the conversion of homocysteine to methionine by the vitamin B₁₂ dependent enzyme, methionine synthase (MS). Impair transmethylation of homocysteine to methionine results in accumulation of homocysteine. A point mutation occurring at 677

nucleotide base pair where replacement of Cytosine to Thymine incorporates Alanine-to-Valine substitution at position 223 of N terminal catalytic domain which decreases enzyme activity.^{6,7}

Individuals with a deficiency of B-vitamins develop severe hyperhomocysteinemia, and this may cause high risk for vascular lesions and thromboembolic events.⁸ Homozygous state of a polymorphic allele in the MTHFR gene is responsible for the thermolabile phenotype which severely attains enzyme MTHFR activity.⁹

To explore lacuna of information about MTHFR gene mutation in Indian population, we took present study and attempted to correlate role of MTHFR mutation with hyperhomocysteinemia in Folate and B₁₂ deficient individuals from south Maharashtra.

Material and Methods

The present study is carried out at Department of Biochemistry, Government Medical College, Miraj and in collaboration with BJMC, Government Medical College, Pune. The study was approved by the local ethics committee. Total 50 cerebrovascular stroke subjects were selected for the study based on clinical evidence and computed tomography scan of the brain. Total 50 numbers of healthy controls with no family history of cerebrovascular stroke were included in the study as controls. The written informed consent was obtained from all subjects. Blood samples were withdrawn from patients after an overnight fast in

vacutainer containing EDTA and plasma was promptly separated. Plasma samples were analyzed for total homocysteine; folic acid and vitamin B₁₂. Packed red cell with buffy coat was preserved at -20°C for DNA extraction.

Homocysteine level in plasma was determined by high performance liquid chromatography (HPLC), coupled with fluorescence detector with internal

standard.¹⁰ Plasma level of folic acid along with vitamin B₁₂ was determined by competitive immunoassay using direct chemiluminescence technology.¹¹ The results were expressed as mean±SD and analyzed by 'z' test.

DNA extraction was carried out by salting out method from frozen venous EDTA blood samples.¹² DNA samples where analyses of polymorphism of C677T mutation in MTHFR enzyme by ARMS PCR.¹³

Table 1: The mutation specific ARMS-PCR primers for MTHFR polymorphism¹⁴

Name	Name of primer (Mutation/ wild specific/ common/ control)	Primer Sequence (5'---3')	Length of Product size
MTHFR	MTHFR:223A (677C)	GAAGGAGAAGGTGTCTGCGGTAGC	197 bp
	MTHFR:223V (677T)	GAAGGAGAAGGTGTCTGCGGAAGT	197 bp
	MTHFR Common	AGGACGGTGCGGTGAGAGTG	
	Control for	CCC ACC TTC CCC TCT CTC CAG GCA AAT GGG	360 bp
	Control RES	GGG CCT CAG TCC CAA CAT GGC TAA GAG GTG	

Frozen DNA samples were dissolved for PCR reaction to get 25 µL reaction mixtures. 25-µL volume containing 1.5 U of Taq DNA polymerase, 1.5 mM MgCl₂, 200 µM each dNTP and 1.5 pmol/50µL MTHFR 677C or MTHFR 677T specific primer, 1.5 pmol/50µL common primers, 8 nmol/L control primer and 2.5µg of DNA. 360 bp fragments of the α₁-antitrypsin gene function as internal control. Amplifications were performed in Quanta Biotech Thermocycler.

The PCR conditions are denaturation for 5 min at 95 °C; followed by 30 cycles at 95 °C for 1 min, 54 °C for 2 min, and 72 °C for 1 min; and a final extension step of 10 min at 72 °C.

Total 10 µl of amplified product was mixed with 2 µl of gel loading dye and separated in a 2% agarose gel that contained 0.1 mg/L ethidium bromide. The samples were electrophoresed for 1 hour at 100 volts, using 1x TAE (Tris-Acetate-EDTA) running buffer. The amplicons were sized using a 100-bp DNA marker.




Fig.1: Genotypes of MTHFR C677T: detected by ARMS- PCR

1-Negative DNA control, 2-Known TT sample, 3-Known CT sample, 4 & 7-Negative for C allele, 5, 6 & 8-Positive for C allele, 9-100 bp DNA ladder.

Statistical analysis: Genotype frequencies with Hardy-Weinberg equilibrium were tested by X² test. The Hardy-Weinberg law defines a simple relationship between the frequencies of genes in the population and frequencies of genotypes.¹⁵

Result

A total of 50 cerebral stroke patients were enrolled with 50 age and sex matched healthy control. We found the mean plasma level of total homocysteine (21.55±3.05 µmol/L) in the study group was significantly higher (P <0.0001) in patients than controls (12.62±1.79 µmol/L). On the other hand plasma Folate level was significantly low (P = 0.0324) in patients (5.61±0.79 ng/mL) as compared to controls (6.75±0.95 ng/mL). Mean vitamin B₁₂ level in patients was 240.20±11.91pg/ml and in control was 272.34±13.05 pg/ml the difference was statistically not significant (P = 0.2602), as depicted in the **Table 2**.

Table 2: Levels of biochemical parameters in study groups

Parameters	Controls (50)	Patients (50)	'P' Value
Homocysteine (µmol/L)	12.62±1.79	21.55±3.05	P < 0.0001
Folic acid (ng/ml)	6.75±0.95	5.61±0.79	P = 0.0324
Vitamin B ₁₂ (pg/ml)	272.34±13.05	240.20±11.91	P = 0.2602

Table 3 shows frequency distribution MTHFR C677T in cerebral stroke patients as well as controls. The occurrence of each polymorphism in control and study group was CC: 68.00% and 60.00%, CT: 28.00% and 32.00%, and for TT: 04.00% and 08.00% respectively.

Table 3: Frequency distribution of MTHFR C677T mutation

Subjects	MTHFR C677T Mutation		
	CC	CT	TT
Control (n=50)	34 (68.00%)	14 (28.00%)	02 (04.00%)
Patients(n=50)	30(60.00%)	16 (32.00%)	04 (08.00%)

Subjects were further classified for the comparison of MTHFR C677T genotypes with values of folic acid, vitamin B₁₂ and total homocysteine levels in cerebrovascular stroke patients and controls are summarized in **Table 4**.

In CC genotype, there was no significant difference in plasma Folate level (P = 0.8854) and vitamin B₁₂ (P = 0.6487) but significantly higher mean value for total homocysteine (P < 0.0001) was observed among patients than controls.

In CT genotype, there was no statistical significant difference found in Folate (P = 0.0288) and vitamin B₁₂ (P = 0.3257), whereas level of total homocysteine (P = 0.0011) were significantly higher in patients than controls.

In TT genotype, the plasma Folate (P = 0.0125) was significantly decreased, whereas total homocysteine (P = 0.0131) was significantly high. There was no statistical difference in vitamin B₁₂ (P = 0.7150) among patients and controls.

Table 4: Levels of biochemical parameters in study groups with distribution of MTHFR C677T mutation

	CC		CT*		TT*	
	Controls (34)	Patients (30)	Controls (14)	Patients (16)	Controls (02)	Patients (04)
Folic acid (ng/ml)	6.17±0.87	6.08±0.86	6.60±0.93	5.64±0.79	6.00±0.85	4.86±0.68
VitB ₁₂ (pg/ml)	284.63±13.60	264.76±2.65	257.55±12.30	220.53±10.54	224.42±10.72	205.88±9.84
tHcy (µmol/L)	10.52±1.49	21.99±3.11*	12.86±1.79	20.30±2.87 *	14.13±2.00	22.14±4.05*

*Statistically significant

Discussion

In last few years, the role of variable genes in the pathogenesis of cerebrovascular stroke has been examined. In particular, the G1691A polymorphism of the factor V gene, the G20210A polymorphism for prothrombin gene, the C677T and A1298C polymorphism of the methylenetetrahydro Folatereductase (MTHFR) gene are among the most frequently studied polymorphisms for ischemic stroke and arteriosclerosis.^{16,17}

In this study, we found that both high plasma concentrations of homocysteine and low plasma concentrations of vitamins Folate and B₁₂ are associated with an increased risk of acute coronary disease and cerebrovascular stroke. Similar combined predictive value of these two parameters was found in various co-workers study.^{18,19,20}

Hyperhomocysteinemia may be due to excessive breakdown of methionine in association with abnormal functioning of vitamin coenzymes and increased body demand of folic acid, vitamin B₁₂, B₆, B₂ either singly or in combination for maintaining of homocysteine²¹ in blood, also excess dietary intake of B-vitamins shows proportionate increased formation of homocysteine. Therefore, formation of homocysteine and reutilization of homocysteine to methionine is not maintained.

The present study shows that, the MTHFR 677 TT genotype was stratified according to their plasma homocysteine level and plasma levels of B-vitamins such as folic acid and B₁₂. Here 677TT polymorphism showed significant high concentration of homocysteine, low concentrations of Folate but statistically no difference in vitamin B₁₂ concentration as compared to controls, the similar results are also reported from other regions,^{22,23,24} hence, plasma total homocysteine with B-vitamins enhanced both thromboembolic and arteriosclerotic process by proliferation of vascular cells, this promotes prothrombotic activity in vascular cell wall. The effect of homocysteine involved in the correlation between allele and arteriosclerosis in the artery demonstrated hyperhomocysteinemia which is a causal risk factor for cerebrovascular diseases. Our results are in agreement with other studies.^{25,26} In other words, elevated level of homocysteine interacts with other conventional risk factors and in combination with these factors increases the risk of arteriothrombotic vascular disease.

Hyperhomocysteinemia was most frequent in patient with cerebral stroke having MTHFR 677TT genotype, may act as an initiator of blood coagulation in vivo. Hence, the MTHFR 677TT genotype may induce cerebral stroke through elevation in homocysteine level.²⁷

The polymorphism of MTHFR gene together with elevated plasma homocysteine level was shown to be associated with developing thrombosis, including cerebrovascular stroke. Hence we propose that MTHFR C677T gene polymorphism is associated with increase plasma homocysteine levels, which is a genetic risk factor for cerebrovascular stroke.

Among Indians, homozygous and heterozygous mutations are observed, but due to lack of research not much data for homocysteine is reported as compared to western population, where homozygous type is predominant.

In conclusion, the MTHFR C677T polymorphism is an independent, non modifiable risk factor, which can lead to cerebrovascular stroke. Individuals having Folate and B₁₂ deficiency are at higher risk, hence should be screened for genetic parameters like MTHFR C677T polymorphism so that appropriate preventive measures can be undertaken and susceptibility for developing disease are reduced.

References

1. Cerebral Embolism Task Force. Cardiogenic brain embolism. *Arch Neurol*. 1986;43:71-84.
2. Lindgren A, Roijer A, Norrving B, Wallin L, Eskilsson J, Johansson BB. Carotid artery and heart disease in subtypes of cerebral infarction. *Stroke*. 1994;25:2356-2362.
3. Panigrahi I, Chatterjee T, Biswas A, Behari M, Choudhry PV, Saxena R. Role of MTHFR C677T polymorphism in ischemic stroke. *Neurol India* 2006;54:48-52.
4. Den Heijer M, Lewington S, Clarke R. Homocysteine, MTHFR and risk of venous thrombosis: a meta-analysis of published epidemiological studies. *J Thromb Haemost*. 2005;3:292-299.
5. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydro Folate reductase. *Nat Genet*. 1995;10:111-113.
6. R Castro, I revera, Pravascocetal. 5,10 methylenetetrahydro Folate reductase (MTHFR) C677T and A1298C mutations are associated with DNA polymorphism. *J Med Genet*. 2004; 41:454-458.
7. Mudd SH, Skovby F, Levy HL, Pettigrew KD, Wilcken B, Pyeritz RE, Andria G, Boers GHJ, Bromberg IL, Cerone R, Fowler B, Grobe H, Schmidt H, Schweitzer L. The natural history of homocystinuria due to cystathionine β-synthase deficiency. *Am J Hum Genet*. 1985;37:1-31.
8. Leo AJ, Kluijtmans, Lambert PWJ, Van den Heuvel, Godfried HJ, Boers, Phyllis Frosst, Erik MB. et al. Molecular Genetic Analysis in Mild Hyperhomocysteinemia: A Common Mutation in the MethylenetetrahydroFolate Reductase Gene Is a Genetic Risk Factor for Cardiovascular Disease. *Am. J. Hum. Genet*. 1996;58:35-41.
9. Naushad S, Nurul Jain Jamal, R Angalena, C Krishna Prasad, A Radha Rama Devi. Hyperhomocysteinemia and the compound heterozygous state for methylene tetrahydro Folate reductase are independent risk factors for deep vein thrombosis among South Indians. *Blood Coagul Fibrinolysis*. 2007;18(2):113-117.
10. Ueland PM, Refsum H, Stabler SP, Malinow MR, Andersson A, Allen RH. Total homocysteine in plasma or serum: methods and clinical applications, *Clin Chem*. 1993; 39(9):1764-1779.
11. Mc Neely MDAJ, Kaplan LA. Folic acid, *Methods in clinical laboratory*, St. Louis. 1987:416-440.
12. Miller SA, Dykes DD, and Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. *Nucleic Acids Research*. 1988;16:1215.
13. Georg Endler, Paul A. Kyrle, Sabine Eichinger, Markus Exner, Christine Mannhalter. Multiplexed Mutagenically Separated PCR: Simultaneous Single-Tube Detection of the Factor V R506Q (G1691A), the Prothrombin G20210A, and the Methylenetetrahydro Folate Reductase A223V (C677T) Variants. *Clinical Chemistry*. 2001;47(2),153-163.
14. Ulvik A, Ren J, Refsum H, Ueland PM. Simultaneous determination of methylene tetrahydro Folate reductase C677T and factor V R506Q genotype by mutagenically separated PCR and multiple-injection capillary electrophoresis. *Clin Chem*. 1998;44(2):264-269.
15. Hardy GH. Mendelian proportions in a mixed population. *Science*. 1908;28:49-50.
16. Kim RJ, Becker RC. Association between factor V Leiden, prothrombin G20210A, and methylenetetrahydro Folate reductase C677T mutations and events of the arterial circulatory system: a meta-analysis of published studies. *Am Heart J*. 2003;146:948-957.
17. Kelly PJ, Rosand J, Kistler JP, Shih VE, Silveira S, Plomaritoglou A, Furie KL. Homocysteine, MTHFR 677C→T polymorphism, and risk of ischemic stroke: results of a meta-analysis. *Neurology*. 2002;59:529-536.
18. Robinson K, Arheart K, Refsum H et al. Low circulating Folate and B6 concentrations. Risk factors for stroke, peripheral vascular disease and coronary artery disease. *Circulation*. 1998;97(5):437-443.
19. Mukhopadhyay K, Dutta S, Das Bhomik A. MTHFR gene polymorphisms analyzed in population from Kolkata, West Bengal. *Indian Journal of Human Genetics*. 2007;13(1):1-38.

20. Bhagwat VR, Yadav AS, Rathod IM. Homocysteine, lipid indices and antioxidants in patients with ischaemic heart disease from Maharashtra, India. *Singapore Med J.* 2009;50:418-24.
21. Evrosvki J, SES, Cole DEC. Clinical Chemistry and molecular biology of Homocysteine metabolism: an update. *Clin Biochem.* 1997;30:189-201.
22. Friso S, Choi SW, Girelli D et al. A common mutation in the 5,10-methylenetetrahydro Folate reductase gene affect genomic DNA methylation through an interaction with Folate status. *Proc Natl Acad Sci USA.* 2002;99:5606-5611.
23. Nabil Mtiraoui, Intissar Ezzidi, Molka Chaieb et al. MTHFR C677T & A1298C gene polymorphism & hyperhomocysteinemia as risk factor of diabetic nephropathy in type-2 diabetes patients, *Diabetes Research and Clinical Practice.* 2007;75:99-106.
24. Frosst P, Blim HJ, Milos R et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydro Folatereductase. *Nat Genet.* 1995;10:111-113.
25. Bova I, Chapman J, Sylantiev C, Korczyn AD, Bornstein NM. The A677V methylenetetrahydro Folate reductase gene polymorphysm and carotid atherosclerosis. *Stroke.* 1999;30:2180-2182.
26. Donner MG, Klein GK, Mathes PB, Schwandt P, Richter WO. Plasma total homocysteine levels in patients with early-onset coronary heart disease and a low cardiovascular risk profile. *Metabolism.* 1998; Mar;47(3):273-9.
27. Biswas A, Ranjan R, Meena A, Akhter MS, Yadav BK, Munisamy M, et al. Homocystine levels, polymorphisms and the risk of ischemic stroke in young Asian Indians. *J Stroke and Cerebrovasc Dis.* 2009;18:103-10.